IONS
NASDAQIonis Pharmaceuticals
$64.28
-20.16 (-23.87%)
2026-07-09 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$14.05B
P/E Ratio
N/A
52W Low
52W High
$60.41
$86.73
Volume
19.7M
Analyst Rating
Hold
Target: $98
12 Analyst Ratings
Strong Buy
0
Buy
0
Hold
12
Sell
0
Price Target Range
Low: $91
Avg: $98
High: $105
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat...
Employees
1,402
Website
ionis.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $944.0M | -40.5% | -$381.0M | -$217.1M |
| 2024 | $705.1M | -67.4% | -$453.9M | -$455.7M |
| 2023 | $787.6M | -44.9% | -$366.3M | -$279.5M |
| 2022 | $587.4M | -69.8% | -$269.7M | -$254.3M |
| 2021 | $810.5M | -3.7% | -$28.6M | $48.7M |
| 2026 Q1 | $246.1M | -47.7% | -$92.5M | -$771.1M |
| 2025 Q4 | $203.0M | -105.9% | -$229.0M | -$116.4M |
| 2025 Q3 | $156.7M | -102.2% | -$128.6M | -$128.1M |
| 2025 Q2 | $452.0M | 30.9% | $123.6M | $165.6M |
| 2025 Q1 | $131.6M | -111.6% | -$146.9M | -$138.2M |
| 2024 Q4 | $226.6M | -48.9% | -$104.3M | -$90.6M |
| 2024 Q3 | $133.8M | -111.1% | -$140.5M | -$105.9M |
| 2024 Q2 | $225.2M | -29.3% | -$66.3M | -$99.6M |